Affiliation:
1. Department of Synthetic Drugs, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland
Abstract
This paper presents the theoretical calculations of the inclusion complex formation between native ceftobiprole, a promising antibiotic from the cephalosporin group, and selected cyclodextrins (CDs) approved by the European Medicines Agency. Ceftobiprole was studied in three protonation states predicted from pKa calculations, along with three selected CDs in a stoichiometric ratio of 1:1. It was introduced into the CD cavity in two opposite directions, resulting in 18 possible combinations. Docking studies determined the initial structures of the complexes, which then served as starting structures for molecular dynamics simulations. The analysis of the obtained trajectories included the spatial arrangement of ceftobiprole and CD, the hydrogen bonds forming between them, and the Gibbs free energy (ΔG) of the complex formation, which was calculated using the Generalised Born Surface Area (GBSA) equation. Among them, a complex of sulfobutyl ether- (SBE-) β-CD with protonated ceftobiprole turned out to be the most stable (ΔG = −12.62 kcal/mol = −52.80 kJ/mol). Then, experimental studies showed changes in the physiochemical properties of the ceftobiprole in the presence of the CDs, thus confirming the validity of the theoretical results. High-performance liquid chromatography analysis showed that the addition of 10 mM SBE-β-CD to a 1 mg/mL solution of ceftobiprole in 0.1 M of HCl increased the solubility 1.5-fold and decreased the degradation rate constant 2.5-fold.
Funder
Polish Ministry of Science and Higher Education
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference42 articles.
1. Lupia, T., Pallotto, C., Corcione, S., Boglione, L., and De Rosa, F.G. (2021). Ceftobiprole perspective: Current and potential future indications. Antibiotics, 10.
2. (2022, August 11). European Medicines Agency Decision P/0311/2020. Available online: https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000205-pip02-11-m04.
3. Electronic Medicines Compendium (EMC) (2023, October 18). Zevtera 500 mg Powder for Concentrate for Solution for Infusion—Summary of Product Characteristics, Available online: https://www.medicines.org.uk/emc/product/9164.
4. Developmental pharmacology and toxicology: Biotransformation of drugs and other xenobiotics during postnatal development;Klinger;Eur. J. Drug Metab. Pharmacokinet.,2005
5. Kesharwani, R., Jaiswal, P., Patel, D.K., and Yadav, P.K. (2022). Lipid-based drug delivery system (LBDDS): An emerging paradigm to enhance oral bioavailability of poorly soluble drugs. Biomed. Mater. Devices.